{
    "root": "225103de-a3f2-47ee-bebb-4aa24b16aab4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Nesina",
    "value": "20250228",
    "ingredients": [
        {
            "name": "ALOGLIPTIN BENZOATE",
            "code": "EEN99869SC"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "nesina® indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus .",
    "contraindications": "recommended patients normal renal function mild renal impairment 25 mg orally daily . ( 2.1 ) taken without food . ( 2.1 ) adjust moderate severe renal impairment end-stage renal disease ( esrd ) . ( 2.2 ) degree renal impairment creatinine clearance ( ml/min ) recommended moderate ≥30 < 60 12.5 mg daily severe/esrd < 30 6.25 mg daily",
    "warningsAndPrecautions": "nesina tablets available film-coated tablets containing 25 mg , 12.5 mg 6.25 mg alogliptin follows : 25 mg tablet : light red , oval , biconvex , film-coated , `` tak alg-25 `` printed one side , available : ndc 64764-250-30 bottles 30 tablets ndc 64764-250-90 bottles 90 tablets ndc 64764-250-50 bottles 500 tablets 12.5 mg tablet : yellow , oval , biconvex , film-coated , `` tak alg-12.5 `` printed one side , available : ndc 64764-125-30 bottles 30 tablets ndc 64764-125-90 bottles 90 tablets ndc 64764-125-50 bottles 500 tablets 6.25 mg tablet : light pink , oval , biconvex , film-coated , `` tak alg-6.25 `` printed one side , available : ndc 64764-625-30 bottles 30 tablets ndc 64764-625-90 bottles 90 tablets",
    "adverseReactions": "nesina contraindicated patients history serious hypersensitivity alogliptin excipients nesina . anaphylaxis , angioedema severe cutaneous reported [ ( 5.3 ) , ( 6.2 ) ] .",
    "indications_original": "NESINA® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "contraindications_original": "The recommended dosage in patients with normal renal function or mild renal impairment is 25 mg orally once daily. ( 2.1 ) Can be taken with or without food. ( 2.1 ) Adjust dosage if moderate or severe renal impairment or end-stage renal disease (ESRD). ( 2.2 ) Degree of Renal Impairment Creatinine Clearance (mL/min) Recommended Dosage Moderate ≥30 to <60 12.5 mg once daily Severe/ESRD <30 6.25 mg once daily",
    "warningsAndPrecautions_original": "NESINA tablets are available as film-coated tablets containing 25 mg, 12.5 mg or 6.25 mg of alogliptin as follows:\n                  25 mg tablet: light red, oval, biconvex, film-coated, with \"TAK ALG-25\" printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                           NDC 64764-250-30\n                           Bottles of 30 tablets\n                        \n                        \n                           NDC 64764-250-90\n                           Bottles of 90 tablets\n                        \n                        \n                           NDC 64764-250-50\n                           Bottles of 500 tablets\n                        \n                     \n                  \n                  12.5 mg tablet: yellow, oval, biconvex, film-coated, with \"TAK ALG-12.5\" printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                           NDC 64764-125-30\n                           Bottles of 30 tablets\n                        \n                        \n                           NDC 64764-125-90\n                           Bottles of 90 tablets\n                        \n                        \n                           NDC 64764-125-50\n                           Bottles of 500 tablets\n                        \n                     \n                  \n                  6.25 mg tablet: light pink, oval, biconvex, film-coated, with \"TAK ALG-6.25\" printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                           NDC 64764-625-30\n                           Bottles of 30 tablets\n                        \n                        \n                           NDC 64764-625-90\n                           Bottles of 90 tablets",
    "adverseReactions_original": "NESINA is contraindicated in patients with a history of serious hypersensitivity to alogliptin or any of the excipients in NESINA. Reactions such as anaphylaxis, angioedema and severe cutaneous adverse reactions have been reported [see Warnings and Precautions (5.3), Adverse Reactions (6.2)]."
}